Diagnostik und Therapie der chronischen pulmonalen Hypertonie
暂无分享,去创建一个
H. Worth | H. Wilkens | R. Ewert | J. Winkler | D. Schranz | F. Reichenberger | I. Schulze-Neick | M. Borst | H. Olschewski | C. Opitz | E. Grünig | F. Kleber | B. Kopp | A. Schmeisser | M. Hoeper
[1] E. Hachulla. Effects of Beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension : a randomized, double-blind, placebo-controlled trial. , 2008 .
[2] F. Herth,et al. Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension , 2006, Circulation.
[3] R. Barst,et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. , 2006, Journal of the American College of Cardiology.
[4] T. Fleming,et al. Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.
[5] T. Welte,et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension , 2005, European Respiratory Journal.
[6] M. Gatzoulis,et al. BREATHE-5: BOSENTAN IMPROVES HEMODYNAMICS AND EXERCISE CAPACITY IN THE FIRST RANDOMIZED PLACEBO-CONTROLLED TRIAL IN EISENMENGER PHYSIOLOGY , 2005 .
[7] D. Badesch,et al. Ambrisentan therapy for pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.
[8] Andres Esteban,et al. Use of sedatives and neuromuscular blockers in a cohort of patients receiving mechanical ventilation. , 2005, Chest.
[9] M. Humbert,et al. Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension , 2005, Circulation.
[10] Horst Olschewski,et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. , 2004, European heart journal.
[11] T. Welte,et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension , 2004, European Respiratory Journal.
[12] C. Bartram,et al. Primary Pulmonary Hypertension in Children May Have a Different Genetic Background Than in Adults , 2004, Pediatric Research.
[13] W. Seeger,et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[14] A. Torbicki,et al. Diagnosis and differential assessment of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[15] P. Corris,et al. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[16] R. Speich,et al. Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.
[17] Paolo Prandoni,et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. , 2004, The New England journal of medicine.
[18] B. Sastry,et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. , 2004, Journal of the American College of Cardiology.
[19] J. Benson,et al. Hepatopulmonary syndrome and portopulmonary hypertension: A report of the multicenter liver transplant database , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[20] F. Reichenberger,et al. Atrial septostomy in the treatment of severe pulmonary arterial hypertension , 2003, Thorax.
[21] W. Seeger,et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.
[22] K. Wasserman,et al. Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.
[23] W. Seeger,et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. , 2003, American journal of respiratory and critical care medicine.
[24] W. Seeger,et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial , 2002, The Lancet.
[25] Gilles Garcia,et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.
[26] W. Seeger,et al. Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.
[27] R. Hetzer,et al. Assessment of Survival in Patients With Primary Pulmonary Hypertension: Importance of Cardiopulmonary Exercise Testing , 2002, Circulation.
[28] R. Ewert,et al. Peripheral airway obstruction in primary pulmonary hypertension , 2002, Thorax.
[29] M. Humbert,et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of the American College of Cardiology.
[30] G. Koch,et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. , 2002, Journal of the American College of Cardiology.
[31] S. Rich,et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.
[32] M. Rubenfire,et al. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.
[33] H. Worth,et al. [Guidelines to long-term oxygen therapy]. , 2001, Pneumologie.
[34] C. Fischer,et al. Abnormal Pulmonary Artery Pressure Response in Asymptomatic Carriers of Primary Pulmonary Hypertension Gene , 2000, Circulation.
[35] S. Hodge,et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. , 2000, American journal of human genetics.
[36] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.
[37] W. Seeger,et al. Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial , 2000, Annals of Internal Medicine.
[38] M. Fujita,et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. , 2000, American journal of respiratory and critical care medicine.
[39] W. Seeger,et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. , 1999, American journal of respiratory and critical care medicine.
[40] R. Barst,et al. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. , 1999, Circulation.
[41] G. Maislin,et al. Vasodilator therapy for primary pulmonary hypertension in children. , 1999, Circulation.
[42] J B Seward,et al. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. , 1998, The American journal of cardiology.
[43] F. Harrell,et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). , 1997, American heart journal.
[44] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[45] S. Rich,et al. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.
[46] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .
[47] E H Bergofsky,et al. Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.
[48] A. Ducoloné,et al. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. , 1981, Thorax.
[49] K. C. Lewis. Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist Sitaxsentan , 2007 .
[50] Avid,et al. BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .
[51] P. Walser,et al. Normal Values for Pulmonary Hemodynamics at Rest and during Exercise in Man , 1975 .